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213Bi-PAI2 conjugate selectively induces apoptosis in PC3
metastatic prostate cancer cell line and shows anti-cancer activity
in a xenograft animal model
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A novel a-particle emitting (
213Bi) plasminogen activator inhibitor type 2 construct, which targets the membrane-bound urokinase
plasminogen activator on prostate cancer cells, was prepared and evaluated in vitro and in a xenograft animal model. The PC3
prostate cancer cell line expresses urokinase plasminogen activator which binds to its receptor on the cell membrane; plasminogen
activator inhibitor type 2 is bound to urokinase plasminogen activator/urokinase plasminogen activator receptor to form stable
complexes. In vitro, the cytotoxicity of
213Bi-plasminogen activator inhibitor type 2 against prostate cancer cells was tested using the
MTS assay and apoptosis was documented using terminal deoxynucleotidyl transferase-mediated deoxyuridinetriphosphate nick
end-labelling (TUNEL) assay. In vivo, antiproliferative effects for tumours and prostate cancer lymph node metastasis were carried
out in an athymic nude mouse model with a subcutaneous xenograft of PC3 cells.
213Bi-plasminogen activator inhibitor type 2 was
speciﬁcally cytotoxic to PC3 cells in a concentration-dependent fashion, causing the cells to undergo apoptosis. A single local or i.p.
injection of
213Bi-plasminogen activator inhibitor type 2 was able to completely regress the growth of tumours and lymph node
metastases 2 days post subcutaneous inoculation, and obvious tumour regression was achieved in the therapy groups compared
with control groups with
213Bi-plasminogen activator inhibitor type 2 when the tumours measured 30–40 mm
3 and 85–
100 mm
3. All control animals and one of ﬁve (20%) mice treated with 3 mCi kg
71 213Bi-plasminogen activator inhibitor type 2
developed metastases in the lymph nodes while no lymphatic spread of cancer was found in the 6 mCi kg
71 treated groups at 2
days and 2 weeks post-cell inoculation. These results demonstrate that this novel
213Bi-plasminogen activator inhibitor type 2
conjugate selectively targets prostate cancer in vitro and in vivo, and could be considered for further development for the therapy of
prostate cancer, especially for the control of micro-metastases or in minimal residual disease.
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Prostate cancer is the second most common cause of death from
cancer in men after lung cancer. An estimated 180400 new cases of
prostate cancer were reported in the USA in 2000 with 31900 deaths
(Greenlee et al, 2000). Although surgical resection or radiotherapy is
potentially curative for localised disease, advanced prostate cancer is
associated with a poor prognosis. The major failure in the manage-
ment of prostate cancer is the inability to inhibit the development
of metastases that eventually result in death of the patient. In spite
of conventional treatments, such as chemotherapy, radiotherapy
and hormone therapy, the control of metastatic prostate cancer
remains elusive. Thus, there is an urgent need for a therapy that
can kill cancer cells in transit or at the pre-angiogenic stage.
The plasminogen activator system has been recognised to play
an important role in tumour growth and metastasis (Pollanen et
al, 1991; Andreasen et al, 1997; Schmitt et al, 2000). Bound to
its speciﬁc cell surface receptor (uPAR), uPA efﬁciently converts
the inactive zymogen plasminogen into the active serine protease,
plasmin, which then cleaves either directly or indirectly extracellu-
lar matrix components including laminin, ﬁbronectin and collagen
(Pollanen et al, 1991; Schmitt et al, 2000). The activity of uPA is
physically regulated by plasminogen activator inhibitors type 1
and 2 (PAI-1 and PAI-2) (Kruithof et al, 1995; Andreasen et al,
1997). PAI-2 is a member of the serine protease inhibitor (Serpin)
superfamily and forms SDS-stable 1:1 complexes with uPA
(Kruithof et al, 1995). It was suggested that cell surface-bound
uPA is accessible to PAI-2, and PAI-2 can inhibit cancer cell inva-
sion and metastasis (Kruithof et al, 1995; Hang et al, 1998).
a-particle therapy has been proposed for use in single-cell disor-
ders such as leukaemias, lymphoma and micrometastatic
carcinomas (Jurcic et al, 1997; McDevitt et al, 1998; Allen, 1999;
Kennel et al, 1999), in which rapid targeting to cancer cells is possible.
The radionuclide
213Bi (t½=46 min) emits an a-particle with short
range (80 mm) and high linear energy transfer (LET) radiation which
is about 100 times greater than that for beta particles (Allen and
Blagojevic, 1997). This is manifested by a high relative biological
effectiveness (RBE). The localisation characteristics of PAI2 allow
213Bi to deliver a large fraction of the total energy to the nucleus of
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www.bjcancer.comthe most malignant prostate cancer cells while irradiation of normal
tissue around the target cell is greatly reduced or absent.
Using
213Bi-PAI2 conjugates, our group successfully targeted
breast cancer in vitro and in vivo (Allen et al, 2000; Ranson et al,
2002). We show herein that
213Bi-PAI2 was speciﬁcally cytotoxic
to PC3 cells in a concentration-dependent fashion, causing the cells
to undergo apoptosis in vitro, whereas a therapeutic dose of
213Bi-
PAI2 obviously regressed tumour growth and prevented metastases
in the lymph nodes in animal models.
MATERIALS AND METHODS
PAI2
Human recombinant PAI2 (47 kD), reactive with the membrane-
bound uPA, was provided by Biotech Australia Pty Ltd.
Conjugation of bifunctional chelate to PAI2
The chelator, cyclic anhydride of diethylenetriaminepentacetic acid
(cDTPA) was purchased from Aldrich Chemical Company. PAI2
and bovine serum albumin (BSA) were conjugated with cDTPA
as described previously (Ranson et al, 2002).
Generation of radioisotopes and
213Bi labelling of
cDTPA-PAI2
The alpha particle emitting radionuclide,
213Bi, was produced from
225Ac/
213Bi generator system.
225Ac column was purchased from the
Department of Energy, USA.
213Bi was eluted from the
225Ac column
with 250 ml of freshly prepared 0.15 M distilled and stabilised hydrio-
dic acid followed by washing with 250 ml water. A time of 2–3 h is
allowed for
213Bi to grow back in the generator for the next elution.
Radiolabelling and puriﬁcation of the PAI2 and BSA constructs with
213Bi were carried out using published methods (Rizvi et al, 2000;
Ransonetal,2002).The labellingefﬁciency of cDTPA-PAI2/BSA with
213Bi was up to 93%. Speciﬁc activity was in the range.
Cell culture
The PC3 human prostate cancer cell line was originally purchased
from American Type Culture Collection (Rockville, MD, USA),
cultured in DMEM (Life Technologies, Inc., Grand Island, NY,
USA) supplemented with 10% (v/v) heated-inactivated foetal
bovine serum (FBS) and 1:100 penicillin/streptomycin. LN3 cells
were originally obtained from Dr C Pettaway (MD Anderson
Hospital) and maintained in 1:1 RPMI-1640:F12-K (Life Technol-
ogies, Inc., Grand Island, NY, USA), supplemented with 10% (v/v)
heated-inactivated foetal calf serum and 1:100 penicillin/strepto-
mycin. Both cell lines were maintained in a humidiﬁed incubator
at 378C and 5% CO2. For all experimental procedures, sub-conﬂu-
ent cells that had been in culture for 48 h without a change of
media were harvested by rinsing ﬂasks twice with Dulbecco’s phos-
phate buffered saline (DPBS) (pH 7.2) and then detaching with
DPBS/0.5 mM EDTA at 378C for 5 min. Cells were collected and
resuspended in the appropriate buffer as described below.
Monoclonal antibodies
Mouse anti-human uAP IgG antibody (No. 394) was purchased
from American Diagnostica Inc (Greenwich, CT, USA). Rabbit
anti-mouse IgG and alkaline phosphatase and anti-alkaline phos-
phatase (APAAP) complex were purchased from Dakopatts
(Glostrup, Denmark). Mouse anti-human isotype control IgG1
monoclonal antibody and goat anti-mouse IgG ﬂuorescein isothio-
cyanate (FITC)-conjugated monoclonal antibody were purchased
from Silenus (Sydney, NSW, Australia).
Flow cytometry
Indirect immunoﬂuorescence staining was performed to detect cell-
surface expression of uPA in the PC3 cell line as described
previously (Ranson et al, 2002).
In vitro cytotoxicity assay
The activities of
213Bi-PAI2 and
213Bi-BSA preparations were
measured using a radioisotope calibrator and neutralised to
pH 7.0 via the addition of 10% (v/v) 1 M NaHCO3 (pH 9.0). After
this, six serial doses of
213Bi-PAI2 and one dose of
213Bi-BSA were
immediately prepared in 100 ml DMEM/5% FBS and added to 96-
well plates in triplicate containing 5610
4 PC3 cells (uPA
+)/100 ml
DMEM/5% FBS or 5610
4 LN3 cells (uPA
-)/100 ml RPMI-1640/5%
FBS. Controls were performed in triplicate in the same 96-well
plate for each experiment and consisted of cDTPA-PAI2 and
DMEM/5% FBS medium alone. The plates were then incubated
overnight in a 5% CO2 atmosphere at 378C.
The cells were then washed and incubated with 100 ml phenol-
red free DMEM (without FBS) containing 20 ml of the CellTiter
96 Aqueous One Solution reagent. After 3 h incubation in a 5%
CO2 atmosphere at 378C, the reaction was stopped by the addition
of 10% SDS, and the absorbency in each well was recorded at
490 nm using a SPECTRO max plate reader (BIO-RAD, Hercules,
CA, USA). The absorbency reﬂects the number of surviving cells.
Blanks were subtracted from all data and analysed using Prism
software (GraphPad Software Inc, USA).
TUNEL assay for apoptosis
The method was performed as described (Li et al, 2001). Brieﬂy,
the cultured PC3 cells were treated with
213Bi-PAI2 in different
concentrations (1, 2.5, 5, 10, and 16 mCi) and with
213Bi-BSA,
cDTPA-PAI2 or medium alone at 378C overnight. After treatment,
cells were washed with DPBS, harvested by centrifugation. Cytospin
preparation were made with a Shando Cyto-centrifuge (Shando,
Pittsburgh, PA, USA). Cell cytospins were prepared on glass slides
using 3610
4 cells per 60 ml per slide. The cells were ﬁxed in 4%
paraformaldehyde at RT for 30 min. Apoptosis was measured using
the TUNEL method (Gavrieli et al, 1992) with TdT-fragEL
tm in situ
apoptotic detection kit according to the manufacturer’s instruction
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Table 1 The effect of
213Bi-PAI2 on PC3 lymph node metastases in nude
mice
Dose Incidence of PC3
Groups (mCi kg
71) metastases
Local injection 2 days post-cell inoculation
PBS buffer 5/5
213Bi-BSA 2.5 5/5
213Bi-PAI2 1.25 2/5
213Bi-PAI2 2.5 0/5
i.p. injection 2 days post-cell inoculation
213Bi-BSA 6.0 5/5
213Bi-PAI2 1.5 3/5
213Bi-PAI2 3.0 1/5
213Bi-PAI2 6.0 0/5
i.p. injection 1 week post-tumour appearance
PAI2* – 5/5
213Bi-PAI2 3.0 1/5
213Bi-PAI2 6.0 0/5
i.p. injection 3 weeks post-tumour appearance
cDTPA-PAI2* – 5/5
213Bi-PAI2 3.0 2/5
213Bi-PAI2 6.0 1/5
Note: For all TAT treatment, we used the same volumes (200 ml). *0.4 mg kg
71 of
PAI2 or cDTPA-PAI2 used equivalent to the highest activity dose of 6 mCi kg
71.
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TUNEL reactivity was conﬁrmed by undertaking in parallel appro-
priate negative (omitting TdT from the labelling mix) and positive
(treated HL-60 slides) control. The labelled cells were examined
using a Leca light microscope (Leica microscope, Nussloch,
Germany) at 640 magniﬁcation. The results were expressed as a
percentage of total cells staining positive for apoptosis.
Animals and PC3 cell inoculation
Male 6–8 weeks old athymic nude mice, BALB/c (nu/nu), were
obtained from Animal Resources Centre (ARC), Western Australia.
The mice were housed and maintained in laminar ﬂow cabinets
under speciﬁc pathogen-free conditions in facilities approved by
University of New South Wales (UNSW) Animal Care and Ethics
Committee (ACEC) and in accordance with their regulations and
standards. The ethical guidelines that were followed meet the stan-
dards required by the UK Coordinating Committee on Cancer
Research Guidelines (Workman et al, 1998).
To establish s.c. tumours, 1.5610
6 PC3 cells were resuspended
in 200 ml of DMEM serum-free medium and injected via 18-gauge
needle into the s.c. space of the right shoulder region. Tumour
progression was documented once weekly by measurements using
calipers, and tumour volumes were calculated by the following
formula: length6width6height60.52 in millimeters (Gleave et
al, 1991). Mice were euthanised by cervical dislocation while under
ethrane anaesthesis.
Treatment protocols
Experiment 1
213Bi-PAI2 at 2 days after PC3 cell inoculation.
Four groups of ﬁve mice each received a single local injection of
213Bi-PAI2 at 25 or 50 mCi,
213Bi-BSA at 50 mCi (non-speciﬁc
controls), or PBS buffer (controls). After 8 weeks, mice were sacri-
ﬁced under anaesthesia, tumours, regional and distant lymph nodes
were excised for histology.
Experiment 2
213Bi-PAI2 at 2 days after PC3 cell inoculation.
Four groups of ﬁve mice each received single i.p. injections of
213Bi-PAI2 at 1.5, 3.0 and 6.0 mCi kg
71 or
213Bi-BSA at
6.0 mCi kg
71. After 8 weeks, the experiment was terminated.
Experiment 3
213Bi-PAI2 at 2 weeks post PC3 cell inoculation
when tumour volumes were approximately 30–40 mm
3. Three
groups of ﬁve mice each received single i.p. injections of
213Bi-
PAI2 at 3.0 and 6.0 mCi kg
71 or PAI2 (0.4 mg kg
71). After 6
weeks, the mice were euthanised.
Experiment 4
213Bi-PAI2 at 4 weeks post PC3 cell inoculation
when tumour volumes were approximately 85–100 mm
3. Groups
of ﬁve mice each received single i.p. injections of
213Bi-PAI2 at
3.0 and 6.0 mCi kg
71 or cDTPA-PAI2 conjugate. After 4 weeks,
mice were euthanised.
Tumour xenograft, lymph node and other organs (liver, spleen,
kidney and lung) from sacriﬁced mice were immediately ﬁxed in
10% neutral buffered formalin for parafﬁn section for uPA expres-
sion and H&E staining.
Immunohistochemistry
The alkaline phosphatase anti-alkaline phosphate (APAAP) method
was used to detect uPA expression in PC3 cells. Cell cytospins were
made on glass slides as described above. Parafﬁn-embedded tissues
were cut at 5 mm sections, mounted on gelatin-coated glass slides
(Davis Gelatine, Australia) and then incubated for 20 min at
608C. The slides were deparafﬁnised in xylene, followed by a
graded series of alcohols (100, 95, and 75%) and rehydrated in
Tris-buffer saline (TBS, pH 7.5). The following steps were also
performed for the PC3 cell glass slides after a 20-min ﬁxation in
4% paraformaldehyde at RT. The primary uPA (20 mgm l
71) was
incubated for 2 h at RT or overnight at 48C. After washing with
Tris buffered saline (TBS), slides including tissue sections or cells
were incubated with rabbit anti-mouse IgG (1:100 dilution) and
APAAP complex (1:100 dilution) for 1 h and then stained by
the addition of a fresh prepared alkaline phosphatase substrate
included 0.2 mg ml
71 of naphthol AS-MX phosphate containing
0.1 mg ml
71 Fast Red TR and Levamisole in 0.1 M Tris HCl
(pH 8.2) for 10 min. The positive cells appear pink.
Statistical analysis
All numerical data were expressed as the average of the values
obtained, and the standard deviation (s.d.) was calculated. For
the in vivo studies, student’s t-test was used to compare data and
results with a P value less than 0.05 were considered statistically
signiﬁcant.
RESULTS
Expression of uPA in PC3 cells, PC3 xenograft tumour and
lymph node metastases
Some 95% of PC3 cells stained positive by immunohistochemistry
for uPA (Figure 1A) while isotype control staining was negative
(data not shown). We conﬁrmed our immunostaining result with
ﬂow cytometry (Figure 1B). The results showed that the uPA histo-
gram has a strong shift to the right compared with the negative
and isotype controls, suggesting that uPA is expressed on the cell
surface and provides a good target for
213Bi-PAI2 conjugate in
vitro. In addition, we also investigated the expression of uPA in
tumour xenografts, lymph nodes containing metastases and other
organs (liver, spleen, kidney and lung) by immunohistochemistry.
The staining intensity of cancer cells in tumour xenograft and
metastasis lymph node was strong (Figure 1C,D); in contrast, the
staining intensity of cells in other organs was very weak or negligi-
ble (data not shown).
213Bi-PAI2 is highly cytotoxic towards the PC3 cells in vitro
213Bi-PAI2 was found to be highly toxic to PC3 cells in an activity
concentration dependent fashion, whereas
213Bi-BSA showed only
slight toxicity compared with
213Bi-PAI2 at the maximum activity
used (Figure 2A). No signiﬁcant toxicity was observed with either
cDTPA-PAI2 or PAI2 (data not shown). The D0 (37% cell survival)
values with
213Bi-PAI2 was calculated to be 3.4 mCi. At the maxi-
mum dose of
213Bi-PAI2 (10 mCi) cell survival was reduced to
10% for PC3 cells while at the same dose of
213Bi-BSA cell survival
was 92%. Additional experiments were designed to test
213Bi-PAI2
against a uPA-negative cancer cell line, LN3. The results indicated
that the D0 value with
213Bi-PAI2 was 43.8 mCi, and a dose of
7.5 mCi
213Bi-PAI2 could kill no more than 15% of LN3 cells
(Figure 2B). These results indicated that the alpha cytotoxicity
was speciﬁc to PC3 cells.
213Bi-PAI2 induces PC3 cells apoptosis
PC3 cells were incubated with increasing concentrations of
213Bi-
PAI2 (1*10 mCi for 24 h) or controls. After treatment,
213Bi-
PAI2-treated cells showed typical apoptotic morphology (Figure
1E), i.e., cells displayed shrinkage, became rounded and detached,
whereas controls and non-speciﬁc
213Bi-BSA-treated cells did not
exhibit apoptotic morphology (Figure 1F). Using an incubation of
5.0 mCi activity
213Bi-PAI2, 90.2+8.4% (mean+s.d., n=3) of the
PC3 cells were TUNEL-positive, in comparision with 8.6+3.5%
(mean+s.d., n=3) of the cells receiving
213Bi-BSA; 4.2+2.2%
(mean+s.d., n=3) of the cells receiving cDTPA-PAI2; 2.1+0.5%
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
213Bi-PAI2 conjugate for prostate cancer
YL iet al
1199
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1197–1203(mean+s.d., n=3) of no treatment control. The free 3' ends gener-
ated by apoptotic DNA cleavage were detected by TUNEL assay, in
which the non-apoptotic cells stained green while apoptotic cells
stained brown. The results were shown in Figure 1G,H.
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Figure 1 uPA expression in PC3 cells, PC3 xenografts and metastatic lymph nodes and TUNEL assay of PC3 cells in vitro.( A) PC3 cells are strongly
positive to membrane-bound uPA. (B) Flow cytometry histogram of PC3 cells showing indirect immunoﬂuorescence labelling of cell surface uPA. Auto:
autoﬂuorescence level; Isotype: mouse anti-human subclasses IgG1 control antibody; uPA: mouse anti-human uPA IgG1 antibody. (C) PC3 tumour xeno-
graft cancer cells are strongly positive to uPA. (D) Cancer cells from metastatic lymph nodes are positive to uPA while lymphocytes are negative to uPA
(small cells). The sections were from different mice. PC3 cells were either treated with
213Bi-PAI 2 (E) or untreated (F). After 36 h, the treated and un-
treated cells were ﬁxed and processed for TUNEL assay. The cells were then visualised by light microscope. The arrows represent typical apoptotic cells
with condensed or fragmented nuclei (G), while control cells show normal shapes (H). A, C, E, F, G and H: Magniﬁcation *6200. D: Magniﬁcation
*6400.
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213Bi-PAI2
Experiment 1 We evaluated the antitumour activity of the
213Bi-
PAI2 given as a single intra-lesional injection of 2 days post-inocu-
lation at 25 and 50 mCi per animal with equal doses of non-speciﬁc
213Bi-BSA or the same volume of PBS buffer. Eight weeks after the
administration of the
213Bi-PAI2, the cancer cells in the 50 mCi
group were completely killed whereas the volume of PC3 tumours
(154+33 mm
3) in the 25 mCi group was signiﬁcantly smaller than
that PBS control group (568+85 mm
3), corresponding to a 73%
inhibition (P50.01; Figure 3A). No obvious inhibition of tumour
growth was observed in mice that received
213Bi-BSA.
Experiment 2 A single i.p. injection of
213Bi-PAI2 was adminis-
tered to mice at 2 days post inoculation at increasing doses of 1.5,
3.0 and 6.0 mCi kg
71. Eight weeks after treatment, PC3 tumour
growth was completely inhibited at a dose of 6.0 mCi kg
71. The
growth of tumours in the 3.0 mCi kg
71 group was delayed 1 week
compared with that in non-speciﬁc control group (Figure 3B). The
volumes for the 1.5 mCi kg
71 group (206+39 mm
3) and in
3.0 mCi kg
71 group (138+48 mm
3) were signiﬁcantly smaller
than that those in the non-speciﬁc control group (428+64 mm
3)
corresponding to 52 and 68% inhibition (P50.01). During the
treatment, no obvious toxicity was observed.
Experiment 3 Treatment was initiated when s.c. tumours had
grown to a volume of 30–40 mm
3. According to the results
obtained from experiment 2, we selected doses of
213Bi-PAI2 at
3.0 and 6.0 mCi kg
71 for i.p. injection. As shown in Figure 3C,
6 weeks after therapy,
213Bi-PAI2 signiﬁcantly inhibited the growth
of PC3 tumours, as evidenced by tumour volumes of
106+20 mm
3 in 6.0 mCi kg
71-treated group and 175+38 mm
3
in 3.0 mCi kg
71-treated group as compared with controls (PAI2
alone) that measured 474+50 mm
3 (78 and 63% reductions,
P50.001).
Experiment 4 Treatment was started when s.c. tumours had
grown to a volume approximately twice as large as those in experi-
ment 3. We used a similar treatment protocol as for experiment 3.
As shown in Figure 3D, 4 weeks post
213Bi-PAI2,
213Bi-PAI2 signif-
icantly regressed the growth of PC3 tumours, as evidenced by
tumour volumes of 148+31 mm
3 in 6.0 mCi kg
71-treated group
and 215+43 mm
3 in 3 mCi kg
71-treated group as compared with
controls (cDTPA-PAI2) that measured 474+50 mm
3 (70 and 55%
reductions, P50.01).
Effect of
213Bi-PAI2 on the development of lymph node
metastases
Eight weeks after s.c. cell inoculation, mice in different groups were
sacriﬁced and examined for lymph node metastases. As assessed by
H&E staining under light microscopy, all control animals including
PBS buffer groups and
213Bi-BSA non-speciﬁc groups developed
metastases in the regional and distant lymph nodes, whereas the
incidence of lymphatic spread was 60% (three out of ﬁve) for
the 1.5 mCi kg
71 i.p. group 2 days post-cell inoculation; 40%
(two out of ﬁve) for 25 mCi local 2 days post-cell inoculation
and 3.0 mCi kg
71 i.p. post-tumour appearance as third week
post-therapy groups; 20% (one out of ﬁve) in 3.0 mCi kg
71 i.p.
2 days post-cell inoculation and 6.0 mCi kg
71 i.p. post-tumour
appearance third week groups. No metastases were found in the
groups given local
213Bi-PAI2 2 days post-inoculation at 50 mCi,
i.p. injection 2 days post-inoculation or post-tumour appearance
ﬁrst week at 6.0 mCi kg
71. The results are shown in Table 1.
DISCUSSION
The present system relies on the targeting of
213Bi to uPA/uPAR
tumour cells. As a result, a much greater fraction of the total
energy is deposited in cells with alpha and very few nuclear hits
are required to kill a cell. The expression of uPA/uPAR was found
on a high percentage of human PC3 prostate cancer line (Crowley
et al, 1993; Festuccia et al, 1998). Using immunocytochemistry and
ﬂow cytometry, we conﬁrmed that uPA/uPAR was expressed on
the surface of viable PC3 cells. In the present study, we also showed
that PC3 tumours and their metastases highly express uPA, which
had not been reported previously. Our ﬁndings indicate that the
PC3 xenograft is an appropriate model for investigating the efﬁcacy
of alpha-PAI2.
PC3 cancer cells are a metastatic cell line while LN3 cells are non-
metastatic and negative to uPA (Evans et al, 1997). PC3 cell kill in
vitro proved to be both speciﬁc and activity dependent. Compared
with untreated and non-speciﬁc controls,
213Bi-PAI2 exhibits high
levels of antigen-selective cytotoxicity, requiring very few
213Bi
atoms per target cell to kill PC3 cells. The D0 value of 3.4 mCi
was found for 50000 cells in 0.3 ml. Thus, 3.4 mCi or 12000 Bq
gives two decays per cell and kills 63% of the incubated cells. This
indicates the speciﬁcity of the conjugate for cells expressing uPA.
Additional data demonstrated that
213Bi-PAI2 did not speciﬁcally
kill the uPA-negative LN3 prostate cancer cell line, supporting the
fact that the
213Bi-PAI2 conjugate does not target or destroy tissue
that does not express uPA. Therefore, it is clear that
213Bi-PAI2 is
an effective and speciﬁc radiolabelled agent for ablation of indivi-
dual PC3 prostate cancer cell in vitro whereas non-targeted cells
are spared from the radiotoxicity arising from the alpha radiation.
The predominant mechanism by which radiation kills mamma-
lian cells is the reproductive (or clonogenic) death pathway. DNA
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Figure 2 Representative cytotoxicity study of (A) PC3 and (B) LN3
prostate cancer cells. Fifty thousand cells were seeded in 0.3 ml medium.
Cells were treated with varying concentrations of
213Bi-PAI2 or non-speci-
ﬁc
213Bi-BSA, incubated overnight and cell survival measured by MTS assay
at 24 h and expressed as a percentage of cell survival of control cells. Re-
sults are expressed as a mean per cent+s.d. of control plates containing
non-speciﬁc a conjugate. Each point represents a mean of three experi-
ments with each experimental point having triplicate wells.
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as the speciﬁc lesions that initiate this lethal response (Radford,
1986; Ward, 1994). Because of very high linear energy transfer
(100 keV mm
71)o fa-particles, cells have a limited ability to repair
the damage to DNA (Nikula et al, 1999). Macklis et al (1992)
reported that a-particles may kill cells by apoptotic mechanisms.
In the present study, we demonstrated that
213Bi-PAI2 can induce
high numbers of TUNEL positive cancer cells compared with
control cells. The results suggest the lethal pathway of PC3 in vitro
after a-PAI2 treatment is predominantly through apoptosis.
The four therapeutic experiments with s.c. xenografts carried out
in vivo were designed to evaluate the antitumour activity and anti-
metastatic effect of
213Bi-PAI2 after administration at different
stages of tumour growth and to optimise the dosage regimen.
Our ﬁndings indicate that a single local injection of
213Bi-PAI2
at a dose of 50 mCi (2.5 mCi kg
71) or a single i.p. injection of
213Bi-PAI2 at a dose of 6 mCi kg
71 can completely suppress
tumour growth and prevent lymph node metastases for at least 8
weeks, while all control animals grew tumours and developed
lymph node metastases. The growth regression of tumours and
metastases was dose-dependent. This means that a proper dose
of
213Bi-PAI2 can kill tumour cells through local or systemic
TAT. A possible explanation of this ﬁnding could be that arresting
the growth of primary tumours with
213Bi-PAI2, also prevents the
dissemination of cancer cells to lymph nodes. At 2 days post inocu-
lation, the seeded PC3 cells are not vascularised and not
encapsulated, and isolated cells and preangiogenic lesions may be
present.
According to our ﬁndings in experiments 3 and 4, a single
systemic (i.p.) injection of
213Bi-PAI2 at doses of 3 and
6 mCi kg
71 during the growth of tumours, when the tumours
were 35 mm
3 (early stage) and 90 mm
3 (late stage) in size, strongly
regressed tumour progression for at least 5–7 weeks. Tumour
volumes in the
213Bi-PAI2-treated groups decreased by 78 and
70% compared to the controls. These results suggest that
213Bi-
PAI2 can still regress the growth of small, solid PC3 tumours
but cannot eradicate them completely. This may be because the
tumour size affects the efﬁcacy of
213Bi-PAI2. It was reported that
radioimmunoconjugate uptake usually decreases due to increased
interstitial pressure (resulting from the lack of functioning lympha-
tic vessels) and restricted blood supply (Jain, 1991). The elevated
interstitial ﬂuid pressure may also act as a physiological barrier
to the delivery of
213Bi-PAI2 conjugates by preventing extravasation
of PAI2 as well.
One interesting ﬁnding of the experiments was that the elimina-
tion of lymph node metastases was dose-dependent. Another
encouraging observation was that using the same amount of
213Bi-PAI2, targeting small primary tumours in the early stage
can more effectively prevent lymph node metastases than larger
tumours as a later stage. A possible interpretation of these ﬁndings
could be that after absorption through the animal peritoneal vascu-
lar system, an effective dose of
213Bi-PAI2 can prevent the
dissemination of the cancer and completely target and kill meta-
static cancer cells or micrometastases that express uPA, leading
to their complete regression. Prostate cancer cells expressing the
prostate speciﬁc membrane antigen (PSMA) can be targeted by
the J591 monoclonal antibody. McDevitt et al (2000) reported that
213Bi-J591 can regress the growth of LNCaP spheroids comprising
*1000 cancer cells in vitro. This in vitro result also supports our in
vivo targeting results. All of these ﬁndings indicate that
213Bi-PAI2
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Figure 3 The effect of a single dose of
213Bi-PAI2 on the growth of s.c. xenografts of PC3 human hormone-independent prostate cancer in nude mice with
localandsystemicinjections.Thearrowsindicatethestartofeachtreatment.(A)Singleintra-lesionalinjectionsof50and25 mCiof
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213Bi-PAI2 or
6.0 mCi kg
71 of
213Bi-BSA were given 2-days post inoculation. (C) Single i.p. injections of 3 and 6 mCi kg
71 of
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(0.4 mg kg
71) were given when tumour volume was 30–40 mm
3.( D) Single i.p. injections of 3 and 6 mCi kg
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cells in transit or at the pre-angiogenic stage, while larger solid
tumours exhibited a growth reduction, but not complete regres-
sion. Therefore, small multiple metastatic sites or minimum
residual disease should be considered to be the most suitable
targets for
213Bi-PAI2.
CONCLUSION
We have shown that TAT using the
213Bi-PAI2 conjugate can: (a)
kill PC3 prostate cancer cells in a dose dependent manner, requir-
ing approximately at two decays per cell for 37% survival; (b)
completely regress tumour growth at 2 days post inoculation using
2.5 mCi kg
71 for local TAT or 6 mCi kg
71 for systemic TAT; (c)
delay tumour growth in a dose dependent way; (d) reduce lymph
node metastases.
ACKNOWLEDGEMENTS
The authors thank Dr Clive Bunn (Human Therapeutics Ltd) for
critical review of the manuscript. We are grateful to Professor J
Kearsley, Director, Cancer Services Division, St George Hospital
for his support, and to the St George and Sutherland Shire
communities for funding that was critical to the survival of the
TAT project. We also thank Professor Pamela J Russell, for kindly
providing LNCap-LN3 prostate cancer cell line with the permission
of Dr C Pettaway, M D Anderson Hospital. This project was
supported in part by a grant from the Kogarah-Carlton Masonic
Lodge.
REFERENCES
Allen BJ, Blagojevic N (1997) Alpha and beta emitting radiolanthanides in
targeted cancer therapy. Nucl Med Commun 17: 40–47
Allen BJ (1999) Can alpha immunotherapy succeed where other systemic
therapies have failed. Nucl Med Commun 20: 205–207
Allen BJ, Rizvi SMA, Li Y, Tian Z, Ranson M (2000) In vitro and preclinical
targeted alpha therapy for melanoma, breast, prostate and colorectal
cancers. Crit Rev Hematol/Oncol 39: 139–146
Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type
plasminogen activator system in cancer metastasis: a review. Int J Cancer
72: 1–22
Crowley CW, Cohen RL, Lucas B, Liu G, Shuman MA, Levinson AD (1993)
Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl
Acad Aci USA 90: 5021–5025
Evans CP, Elfman F, Parangi S, Conn M, Cunha G, Shuman MA (1997) Inhi-
bition of prostate cancer neovascularization and growth by urokinase-
plasminogen activator receptor blockade. Cancer Res 57: 3594–3599
Festuccia C, Dolo V, Guerra F, Violini S, Muzi P, Pavan A, Bologna M (1998)
Plasminogen activator system modulates invasive capacity and prolifera-
tion in prostatic tumor cells. Clin Exp Metast 16: 513–528
Gavrieli Y, Sherman Y, Ben-Sasson SA (1992) Identiﬁcation of programmed
cell death in situ via speciﬁc labeling of nuclear DNA fragmentation. J Cell
Biol 119: 493–501
Gleave M, Hseih JT, Gao C, von Eschenbach AC, Chung LKW (1991) Accel-
eration of human prostate cancer in vivo by factors produced by prostate
and bione ﬁbroblasts. Cancer Res 51: 3753–3761
Greenlee R, Murray T, Bolden S, Wingo PA (2000) Cancer statistics. CA.
Cancer J Clin 50: 7–33
Hang MTN, Ranson M, Saunders DN, Liang XM, Bunn CL, Baker MS (1998)
Pharmacokinetics and biodistribution of recombinant human plasmino-
gen activator inhibitor type 2 (PAI-2) in control and tumour xenograft-
bearing mice. Fibrinol Proteol 12: 145–154
Jain RK (1991) Haemodynamic and transport barriers to the treatment of
solid tumors. Int J Radiat Biol 60: 85
Jurcic JG, McDevitt MR, Sgouros G, Ballangrud AM, Finn RD, Geerlings
MWSR, Humm JL, Molinet R, Apostolidis C, Larson SM, Scheinberg
DA (1997) Targeted therapy for myeloid leukemias: a phase I trial of
bismuth-213-HuM195 (anti-CD33). Blood 90(Suppl 1): 2245
Kennel SJ, Boll R, Stabin M, Schuller HM, Mirzadeh S (1999) Radioimmu-
notherapy of micrometastases in lung with vascular targeted
213Bi. Br J
Cancer 80: 175–184
Kruithof EKO, Baker MS, Bunn CL (1995) Biochemistry, cellular and mole-
cular biology and clinical aspects of plasminogen activator inhibitor type-
2. Blood 86: 4007–4024
Li Y, Tian Z, Rizvi SMA, Bander NH, Allen BJ (2001) In vitro and preclinical
targeted alpha therapy of human prostate cancer with Bi-213 labeled J591
antibody against the prostate speciﬁc membrane antigen. Prost Cancer
Prost Dis 4: 1–11
Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL (1992)
Cellular kinetics, dosimetry, and radiobiology of a-particle radioimmu-
notherapy: induction of apoptosis. Radiat Res 130: 220–226
McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, Schein-
berg DA (1998) Radioimmunotherapy with alpha-emitting nuclides. Eur J
Nucl Med 25: 1341–1351
McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, Ballan-
grud A M, Yang WH, Finn RD, Pellegrini V, Geerlings, MW, Lee M,
Brechbiel MW, Bander NH, Cordon-Cardo C, Scheinberg DA (2000) An
a-particle emitting antibody ([
213Bi]J591) for radioimmunotherapy of
prostate cancer. Cancer Res 60: 6059–6100
Nikula TK, McDevitt MR, Finn RD, Wu C, Kozak RW, Garmestani K, Brech-
biel MW, Curcio MJ, Pippin CG, Tiffany-Jones L, Geerlings Sr MW,
Apostolidis C, Molinet R, Geerlings Jr MW, Gansow OT, Scheinberg DA
(1999) Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of
recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioac-
tivity, toxicity and chemistry. J Nucl Med 40: 166–176
Pollanen J, Stephens R, Vaheri A (1991) Directed plasminogen activation at
the surface of normal and malignant cells. Adv Cancer Res 57: 273–328
Radford IR (1986) Evidence for a general relationship between the induced
level of DNA double-stranded breakage and cell-killing after X-irradiation
of mammalian cells. Int J Radiat Biol Relat Stud Phys Chem Med 49: 611–
620
Ranson M, Tian Z, Andronicos NM, Rizvi SMA, Allen BJ (2002) In vitro cyto-
toxicity study of human breast cancer cells using Bismuth-213 (
213Bi)-
labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2). Breast
Cancer Res Treat 71: 149–151
Rizvi SMA, Sarkar S, Goozee G, Allen BJ (2000) Radioimmunoconjugates for
targeted alpha therapy of malignant melanoma. Melanoma Res 10: 281–
290
Schmitt M, Wilhelm OG, Reuning U, Kruger A, Harbeck N, Lengyel E, Graeff
H, Gansbacher B, Kessler H, Burgle M, Sturzebecher J, Sperl S, Magdolen
V (2000) The urokinase plasminogen activation system as a novel target for
tumour therapy. Fibrinol Proteol 14: 114–132
Ward JF (1994) The complexity of DNA damage: relevance to biological
consequences. Int J Radiat Biol 66: 427–442
Workman P, Twentyman P, Balkwill F, Balmain A, Chaplin D, Double J,
Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J
(1998) United Kingdom Coordinating Committee guidelines for the
welfare of animals in experimental neoplasia (second edition). Br J Cancer
77: 1–10
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
213Bi-PAI2 conjugate for prostate cancer
YL iet al
1203
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1197–1203